Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Assets Average (2023 - 2025)

Monte Rosa Therapeutics' Assets Average history spans 3 years, with the latest figure at $454.2 million for Q4 2025.

  • For Q4 2025, Assets Average rose 20.52% year-over-year to $454.2 million; the TTM value through Dec 2025 reached $454.2 million, up 20.52%, while the annual FY2025 figure was $443.7 million, 19.52% up from the prior year.
  • Assets Average reached $454.2 million in Q4 2025 per GLUE's latest filing, up from $409.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $454.2 million in Q4 2025 to a low of $265.4 million in Q3 2023.
  • Average Assets Average over 3 years is $344.6 million, with a median of $329.6 million recorded in 2024.
  • Peak YoY movement for Assets Average: increased 3.95% in 2024, then soared 45.82% in 2025.
  • A 3-year view of Assets Average shows it stood at $277.9 million in 2023, then surged by 35.61% to $376.9 million in 2024, then rose by 20.52% to $454.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Assets Average are $454.2 million (Q4 2025), $409.7 million (Q3 2025), and $376.4 million (Q2 2025).